Rates of cannabis use are increasing in the United States, likely as a result of changes in societal attitudes and expanding legalization. Although many patients report wanting to discuss the risks and benefits of cannabis use with their clinical providers, many providers hold conflicting beliefs regarding cannabis use and often do not engage patients in discussion about cannabis. This dilemma is underscored by the limitations imposed on cannabis related research, and lack of empirically based best-practice guidelines for clinicians when addressing cannabis use with patients.
Objectives:
We aimed to briefly summarize clinician and patient attitudes toward cannabis use and review current clinical guidelines and provide suggestions to assist health care providers and clinicians in increasing their comfort and skill in discussing cannabis use with patients.
Methods:
A narrative review on attitudes toward cannabis use and clinical guidelines was performed to summarize the literature and provide evidence-based recommendations.
Results:
Attitudes toward cannabis use have been shaped by personal and political factors and contribute to clinician hesitance in speaking with patients about the topic. Administrative barriers have hindered the development of clearer public health guidelines that might enable the dissemination of evidence-based information on the health effects of cannabis use and might ultimately lead to better health outcomes.
Conclusion:
Not discussing cannabis use with patients may be a crucial missed opportunity for harm reduction. In the absence of empirically supported best-practice guidelines, a person-centered approach can facilitate conversations on the harms and benefits of cannabis use.
National Academies of Sciences Engineering and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press; 2017.
2.
WeaverMFJarvisMAESchnollSH.Role of the primary care physician in problems of substance abuse. Arch Intern Med. 1999;159(9):913-924. doi:10.1001/archinte.159.9.913
3.
CarliniBHGarrettSBCarterGT.Medicinal cannabis: A survey among health care providers in Washington State. Am J Hosp Palliat Care. 2017;34(1):85-91. doi:10.1177/1049909115604669
4.
ZolotovYVulfsonsSZarhinDSznitmanS.Medical cannabis: An oxymoron? Physicians’ perceptions of medical cannabis. Int J Drug Policy. 2018;57:4-10. doi:10.1016/j.drugpo.2018.03.025
5.
PhilpotLMEbbertJOHurtRT.A survey of the attitudes, beliefs and knowledge about medical cannabis among primary care providers. BMC Fam Pract. 2019;20(1):17. doi:10.1186/s12875-019-0906-y
6.
BraunIMWrightAPeteetJ, et al. Medical oncologists’ beliefs, practices, and knowledge regarding marijuana used therapeutically: A nationally representative survey study. J Clin Oncol. 2018;36(19):1957-1962. doi:10.1200/JCO.2017.76.1221
7.
McLennanAKerbaMSubnisUCampbellTCarlsonLE.Health care provider preferences for, and barriers to, cannabis use in cancer care. Curr Oncol. 2020;27(2):199-205. doi:10.3747/co.27.5615
8.
BlevinsCERawatNSteinMD.Gaps in the substance use disorder treatment referral process: Provider perceptions. J Addict Med. 2018;12(4):273-277. doi:10.1097/ADM.0000000000000400
9.
BoehnkeKFLitinasEWorthingBConineLKrugerDJ.Communication between healthcare providers and medical cannabis patients regarding referral and medication substitution. J Cannabis Res. 2021;3(1):2. doi:10.1186/s42238-021-00058-0
10.
EbbertJOScharfELHurtRT.Medical cannabis. Mayo Clin Proc. 2018;93(12):1842-1847. doi:10.1016/j.mayocp.2018.09.005
11.
McNeelyJKumarPCRieckmannT, et al. Barriers and facilitators affecting the implementation of substance use screening in primary care clinics: a qualitative study of patients, providers, and staff. Addict Sci Clin Pract. 2018;13(1):8. doi:10.1186/s13722-018-0110-8
12.
United States Pharmacopœial Convention. The Pharmacopoeia of the United States of America. Wells and Lilly for Charles Ewer; 1916.
13.
SmithR. U. S.Marijuana legislation and the creation of a social problem. J Psychedelic Drugs. 1968;2(1):93-104. doi:10.1080/02791072.1968.10524403
14.
GriffinOHFritschALWoodwardVHMohnRS.Sifting through the hyperbole: one hundred years of marijuana coverage in The New York Times. Deviant Behav. 2013;34(10):767-781. doi:10.1080/01639625.2013.766548
15.
ReidM.A qualitative review of cannabis stigmas at the twilight of prohibition. J Cannabis Res. 2020;2(1):46. doi:10.1186/s42238-020-00056-8
BachmanJGJohnsonLDO’MalleyPM.Explaining recent increases in students’ marijuana use: impacts of perceived risks and disapproval, 1976 through 1996. Am J Public Health. 1998;88(6):887-892. doi:10.2105/AJPH.88.6.887
FelsonJAdamczykAThomasC.How and why have attitudes about cannabis legalization changed so much?Soc Sci Res. 2019;78:12-27. doi:10.1016/j.ssresearch.2018.12.011
22.
ComptonWMHanBJonesCMBlancoCHughesA.Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys. Lancet Psychiatry. 2016;3(10):954-964. doi:10.1016/S2215-0366(16)30208-5
23.
CarlinerHBrownQLSarvetALHasinDS.Cannabis use, attitudes, and legal status in the U.S.: a review. Prev Med. 2017;104:13-23. doi:10.1016/j.ypmed.2017.07.008
HasinDSShmulewitzDSarvetAL.Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings. Am J Drug Alcohol Abuse. 2019;45(6):623-643. doi:10.1080/00952990.2019.1569668
30.
DavenportSSCaulkinsJP.Evolution of the United States Marijuana market in the decade of liberalization before full legalization. J Drug Issues. 2016;46(4):411-427. doi:10.1177/0022042616659759
31.
KilmerBCaulkinsJKilbornMPriestMWarrenK.Cannabis legalization and social equity: some opportunities, puzzles, and trade-offs. Boston Univ Law Rev. 2021;(101): 1003–1041.
32.
Center for Behavioral Health Statistics and Quality. Racial/Ethnic Differences in Substance Use, Substance Use Disorders, and Substance Use Treatment Utilization among People Aged 12 or Older (2015-2019). Substance Abuse and Mental Health Services Administration; 2021. https://www.samhsa.gov/data/
33.
PhilbinMMMauroPMGreeneERMartinsSS.State-level marijuana policies and marijuana use and marijuana use disorder among a nationally representative sample of adults in the United States, 2015-2017: Sexual identity and gender matter. Drug Alcohol Depend. 2019;204:107506. doi:10.1016/j.drugalcdep.2019.06.009
34.
BargerBTObedin-MaliverJCapriottiMRLunnMRFlentjeA.Characterization of substance use among underrepresented sexual and gender minority participants in the population research in identity and disparities for equality (PRIDE) study. Subst Abuse. 2021;42(1):104-115. doi:10.1080/08897077.2019.1702610
35.
NIH RePORT. Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC). National Institutes of Health (NIH); 2021. Accessed October 16, 2021. https://report.nih.gov/funding/categorical-spending#/
36.
National Academies of Sciences Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, et al. Challenges and Barriers in Conducting Cannabis Research. National Academies Press (US);2017. Accessed October 16, 2021. https://www.ncbi.nlm.nih.gov/books/NBK425757/
37.
StithSSVigilJM.Federal barriers to Cannabis research. Science. 2016;352(6290):1182. doi:10.1126/science.aaf7450
38.
CashMCCunnaneKFanCRomero-SandovalEA.Mapping cannabis potency in medical and recreational programs in the United States. PLOS ONE. 2020;15(3):e0230167. doi:10.1371/journal.pone.0230167
39.
CarliniBH.Potency increase, product development and marijuana marketing in times of legalization. Addiction. 2017;112(12):2178-2179. doi:10.1111/add.13945
40.
MatsonTECarrellDSBobbJF, et al. Prevalence of medical cannabis use and associated health conditions documented in electronic health records among primary care patients in Washington State. JAMA Netw Open. 2021;4(5):e219375. doi:10.1001/jamanetworkopen.2021.9375
41.
LyonL.THC and CBD: is medical cannabis overhyped or under-prescribed?Brain. 2020;143(4):e34-e34. doi:10.1093/brain/awaa066
PhillipsKAThrushPTLalAK, et al. Marijuana in pediatric and adult congenital heart disease heart transplant listing: a survey of provider practices and attitudes. Pediatr Transplant. 2020;24(2):e13640. doi:10.1111/petr.13640
44.
SobeskyMGorgensK.Cannabis and adolescents: Exploring the substance misuse treatment provider experience in a climate of legalization. Int J Drug Policy. 2016;33:66-74. doi:10.1016/j.drugpo.2016.02.008
CollenM.Prescribing cannabis for harm reduction. Harm Reduct J. 2012;9(1):1. doi:10.1186/1477-7517-9-1
47.
MikuriyaTH.Cannabis as a substitute for alcohol: A harm-reduction approach. J Cannabis Ther. 2004;4(1):79-93. doi:10.1300/J175v04n01_04
48.
DenhamBE.Attitudes toward legalization of marijuana in the United States, 1986-2016: changes in determinants of public opinion. Int J Drug Policy. 2019;71:78-90. doi:10.1016/j.drugpo.2019.06.007
49.
BrooksEGundersenDCFlynnEBrooks-RussellABullS.The clinical implications of legalizing marijuana: are physician and non-physician providers prepared?Addict Behav. 2017;72:1-7. doi:10.1016/j.addbeh.2017.03.007
50.
CookeACKnightKRMiaskowskiC.Patients’ and clinicians’ perspectives of co-use of cannabis and opioids for chronic non-cancer pain management in primary care. Int J Drug Policy. 2019;63:23-28. doi:10.1016/j.drugpo.2018.09.002
51.
GrayTREidenRDLeonardKEConnorsGJShislerSHuestisMA.Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth. Clin Chem. 2010;56(9):1442-1450. doi:10.1373/clinchem.2010.147876
52.
GunnJKLRosalesCBCenterKE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986. doi:10.1136/bmjopen-2015-009986
53.
HasinDS.US epidemiology of cannabis use and associated problems. Neuropsychopharmacology. 2018;43(1):195-212. doi:10.1038/npp.2017.198
54.
CerdáMMauroCHamiltonA, et al. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatry. 2020;77(2):165. doi:10.1001/jamapsychiatry.2019.3254
55.
BudneyAJSofisMJBorodovskyJT.An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use. Eur Arch Psychiatry Clin Neurosci. 2019;269(1):73-86. doi:10.1007/s00406-018-0976-1
56.
FergussonDMBodenJMHorwoodLJ.Psychosocial sequelae of cannabis use and implications for policy: findings from the christchurch health and development study. Soc Psychiatry Psychiatr Epidemiol. 2015;50(9):1317-1326. doi:10.1007/s00127-015-1070-x
57.
PrattMStevensAThukuM, et al. Benefits and harms of medical cannabis: a scoping review of systematic reviews. Syst Rev. 2019;8(1):320. doi:10.1186/s13643-019-1243-x
58.
López-PelayoHBatallaABalcellsMMColomJGualA.Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments. Psychol Med. 2015;45(6):1121-1133. doi:10.1017/S0033291714002463
59.
Bonn-MillerMOHeinzAJSmithEVBrunoRAdamsonS.Preliminary development of a brief cannabis use disorder screening tool: the cannabis use disorder identification test short-form. Cannabis Cannabinoid Res. 2016;1(1):252-261. doi:10.1089/can.2016.0022
60.
MatsonTELaphamGTBobbJF, et al. Validity of the single-item screen–cannabis (SIS-C) for cannabis use disorder screening in routine care. JAMA Netw Open. 2022;5(11):e2239772. doi:10.1001/jamanetworkopen.2022.39772
61.
Roy-ByrnePMaynardCBumgardnerK, et al. Are medical marijuana users different from recreational users? The view from primary care. Am J Addict. 2015;24(7):599-606. doi:10.1111/ajad.12270
62.
WoodruffSIShillingtonAM.Sociodemographic and drug use severity differences between medical marijuana users and non-medical users visiting the emergency department. Am J Addict. 2016;25(5):385-391. doi:10.1111/ajad.12401
63.
WilsonJMillsKFreemanTPSunderlandMVisontayRMarelC.Weeding out the truth: a systematic review and meta-analysis on the transition from cannabis use to opioid use and opioid use disorders, abuse or dependence. Addiction. 2022;117(2):284-298. doi:10.1111/add.15581
64.
CoughlinLNLinLABonarEE.An agenda for research to transform care for cannabis use disorder. Addict Behav. Published online June 12, 2023. doi:10.1016/j.addbeh.2023.107774
65.
BarlowDHNockMK.Why can’t we be more idiographic in our research?Perspect Psychol Sci. 2009;4(1):19-21. doi:10.1111/j.1745-6924.2009.01088.x
66.
FisherAJ.Toward a dynamic model of psychological assessment: implications for personalized care. J Consult Clin Psychol. 2015;83(4):825-836. doi:10.1037/ccp0000026
67.
HaynesSNMummaGHPinsonC.Idiographic assessment: conceptual and psychometric foundations of individualized behavioral assessment. Clin Psychol Rev. 2009;29(2):179-191. doi:10.1016/j.cpr.2008.12.003
68.
PiccirilloMLRodebaughTL.Foundations of idiographic methods in psychology and applications for psychotherapy. Clin Psychol Rev. 2019;71:90-100. doi:10.1016/j.cpr.2019.01.002
69.
FisherAJMedagliaJDJeronimusBF.Lack of group-to-individual generalizability is a threat to human subjects research. Proc Natl Acad Sci. 2018;115(27):E6106-E6115. doi:10.1073/pnas.1711978115
70.
McCormackBMcCanceTV.Development of a framework for person-centred nursing. J Adv Nurs. 2006;56(5):472-479. doi:10.1111/j.1365-2648.2006.04042.x
71.
Substance Aubse and Mental Health Services Administration. Know the risks of marijuana. Accessed March 10, 2022. https://www.samhsa.gov/marijuana
72.
JohnsonECDemontisDThorgeirssonTE, et al. A large-scale genome-wide association study meta-analysis of cannabis use disorder. Lancet Psychiatry. 2020;7(12):1032-1045. doi:10.1016/S2215-0366(20)30339-4
73.
PintoJVMedeirosLSSantanadaRosaG, et al. The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: a systematic review with meta-analysis and meta-regression. Neurosci Biobehav Rev. 2019;101:78-84. doi:10.1016/j.neubiorev.2019.04.004
74.
LiuYWilliamsonVSetlowBCottlerLBKnackstedtLA.The importance of considering polysubstance use: lessons from cocaine research. Drug Alcohol Depend. 2018;192:16-28. doi:10.1016/j.drugalcdep.2018.07.025
75.
HaynesSNO’BrienWH.Functional analysis in behavior therapy. Clin Psychol Rev. 1990;10(6):649-668. doi:10.1016/0272-7358(90)90074-K
76.
GreenhalghTThorneSMalterudK.Time to challenge the spurious hierarchy of systematic over narrative reviews?Eur J Clin Invest. 2018;48(6):e12931. doi:10.1111/eci.12931
ShahSSchwenkESSondekoppamRV, et al. ASRA pain medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. Reg Anesth Pain Med. 2023;48(3):97-117. doi:10.1136/rapm-2022-104013
ShapiroBCoffaDMcCance-KatzEF.A primary care approach to substance misuse. Am Fam Physician. 2013;88(2):113-121.
82.
Calomarde-GómezCJiménez-FernándezBBalcells-OliveróMGualALópez-PelayoH.Motivational interviewing for cannabis use disorders: a systematic review and meta-analysis. Eur Addict Res. 2021;27(6):413-427. doi:10.1159/000515667
83.
PollakKIBackALTulskyJA.Disseminating effective clinician communication techniques: engaging clinicians to want to learn how to engage patients. Patient Educ Couns. 2017;100(10):1951-1954. doi:10.1016/j.pec.2017.05.015
84.
RollnickSMillerWR.What is motivational interviewing?Behav Cogn Psychother. 1995;23(4):325-334. doi:10.1017/S135246580001643X
85.
Welcome to the Motivational Interviewing Website! | Motivational interviewing network of trainers (MINT). Accessed March 8, 2023. https://motivationalinterviewing.org/
86.
HargravesDWhiteCFrederickR, et al. Implementing SBIRT (Screening, brief intervention and referral to treatment) in primary care: lessons learned from a multi-practice evaluation portfolio. Public Health Rev. 2017;38(1):31. doi:10.1186/s40985-017-0077-0
